The EMBRAVE Study
TM
for children with early-onset SCN2A Developmental and Epileptic Encephalopathies (DEE)
Thank you for your interest in the PRAX-222-111 EMBRAVE study for children with SCN2A early-onset Development and Epileptic Encephalopathy (DEE). Enrollment into the Part 1 cohort of the EMBRAVE study has concluded. To learn the latest updates on the EMBRAVE study, click the link below.
If you would like to be notified when the next phase of the EMBRAVE study is initiated, please schedule a call with our Nurse Patient Navigator.
About PRAX-222
PRAX-222 is an investigational antisense oligonucleotide (ASO) with the potential to be the first disease-modifying treatment for early-onset SCN2A Developmental and Epileptic Encephalopathy (DEE).
An ASO is a short, synthetic segment of genetic sequence designed to correct the malfunction in a specific gene. In animal studies, PRAX-222 was shown to significantly reduce seizures, normalize developmental curves and improve survival. By targeting the underlying genetic cause of disease, PRAX-222 has demonstrated potential to go beyond seizures to treating other symptoms of the disease.
Speak to a nurse about the EMBRAVE Study
To schedule call with a Praxis Nurse Patient Navigator:
1. Please review the consent below.
2. Once you click "Schedule a call" a calendar will open,
and you can select a day and time to speak with the EMBRAVE nurse navigator.